Cargando…

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Shinsuke, Toyoma, Satoshi, Kawasaki, Yohei, Koizumi, Koh, Iikawa, Nobuko, Shiina, Kazuhiro, Endo, Tentaro, Abe, Tomoe, Kouga, Teppei, Yamada, Takechiyo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621992/ https://www.ncbi.nlm.nih.gov/pubmed/34833369 http://dx.doi.org/10.3390/medicina57111151

Ejemplares similares

18F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

SDF-1/CXCR4 induces cell invasion through CD147 in squamous cell carcinoma of the hypopharynx
por: Toyoma, Satoshi, et al.
Publicado: (2020)

Intrinsic Oncogenic Function of Intracellular Connexin26 Protein in Head and Neck Squamous Cell Carcinoma Cells
por: Iikawa, Nobuko, et al.
Publicado: (2018)

Investigation of Cry J1 and Cry J2 Concentrations in Japanese Cedar Pollen and Non-Pollen Seasons
por: Tomizawa, Hiroki, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma
por: Suzuki, Hitomi, et al.
Publicado: (2022)

CD98hc as a marker of radiotherapy-resistant cancer stem cells in head and neck squamous cell carcinoma
por: Kawasaki, Yohei, et al.
Publicado: (2020)

CD147 expression correlates with lymph node metastasis in T1-T2 squamous cell carcinoma of the tongue
por: Suzuki, Shinsuke, et al.
Publicado: (2017)

The investigation of salvage endoscopic laryngopharyngeal surgery after chemoradiotherapy
por: Kawasaki, Yohei, et al.
Publicado: (2020)

An investigation on endoscopic laryngopharyngeal surgery and related outcomes
por: Kawasaki, Yohei, et al.
Publicado: (2018)

LAT1 is associated with poor prognosis and radioresistance in head and neck squamous cell carcinoma
por: Kawasaki, Yohei, et al.
Publicado: (2023)

GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma—Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis
por: Kawasaki, Yohei, et al.
Publicado: (2022)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

Efficacy of Arytenoidectomy after Suture Lateralisation Failure in Patients with Bilateral Vocal Cord Paralysis
por: Suzuki, Shinsuke, et al.
Publicado: (2020)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
por: Noronha, Vanita, et al.
Publicado: (2017)

Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition
por: Lin, Yu-Wei, et al.
Publicado: (2017)

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study
por: Wakasaki, Takahiro, et al.
Publicado: (2022)

Eotaxin-3 as a Plasma Biomarker for Mucosal Eosinophil Infiltration in Chronic Rhinosinusitis
por: Yamada, Takechiyo, et al.
Publicado: (2019)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
por: Sawatani, Yuta, et al.
Publicado: (2020)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
por: Zheng, Yanqing, et al.
Publicado: (2021)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia
por: Arai, Makoto, et al.
Publicado: (2023)

Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
por: Yoshioka, Keiichiro, et al.
Publicado: (2022)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Retracted: “Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial”
Publicado: (2023)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
por: Takeshita, Naohiro, et al.
Publicado: (2022)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
por: Enokida, Tomohiro, et al.
Publicado: (2020)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
por: Lu, Zhihao, et al.
Publicado: (2022)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9n34i6b3qi6pfp9ib34vo1fag